
ALTONA RARE EARTHS PLC
("Altona" or "the Company")
RESEARCH NOTE
Altona (LSE: REE), a resource exploration and development company focused on critical raw materials in
https://www.optimocapital.co.uk/s/Altona_Rare_Earths_Update_Optimo-Sep_2025-f3zm.pdf
To subscribe for RNS alerts, please join our investor hub on: https://investors.altonare.com/auth/signup
-ends-
Louise Adrian, CFO +44 (0) 7721 492 922
Strand Hanson (Financial Adviser) +44 (0) 20 7409 3494
Christopher Raggett
Imogen Ellis
Nick Lovering
Adam Pollock
Aimee McCusker
About
The multi-commodity
In parallel, Altona is progressing plans to fast-track the development of high-grade fluorspar veins identified along the western and southern margins of Monte Muambe, with a targeted production of 50,000 tonnes per annum of acid-grade fluorspar over a minimum 12-year mine life. Acid-grade fluorspar is a key input in a wide range of applications, including hydrofluoric acid and lithium battery electrolyte production, placing Altona in a strong position to supply this critical material.
The discovery of gallium mineralisation, with grades up to 550 g/t identified to date, adds further value to Monte Muambe. The Company is undertaking mineralogical and metallurgical studies to assess the potential for gallium production.
Altona's diversified portfolio also includes the
With a unique combination of critical raw materials projects, Altona is well positioned to contribute to the global supply of highly sought commodities essential for clean energy, high technology, defence and industrial applications.
The Company and the Board remain actively focused on identifying and evaluating additional projects that align with our investment profile and strategic objectives, leveraging our extensive network and combined industry experience to uncover compelling opportunities that can drive long-term growth.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the